In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15m in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora Cream.
Almirall and MC2 Therapeutics partner to make Wynzora Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25m units in sales volume annually.
The market represents a significant opportunity for Wynzora Cream as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than USD 300m.
Wynzora Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th July 2020. Wynzora Cream is currently under review in Europe supported by two Phase 3 trials, including an EU head-to-head trial against active comparator Dovobet/Daivobet Gel.
The Physician Global Assessment treatment success defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at Week 8 was 51% for Wynzora Cream vs. 6% for vehicle (p
AstraZeneca and FibroGen provide update on FDA review of roxadustat
Quidel awarded FDA's EUA for prescribed QuickVue At-Home COVID-19 Test with results in ten minutes
QureBio's Q-1802 receives US FDA Investigational New Drug application approval
J&J waiting regulatory approval for new plant to deliver high volumes of COVID-19 vaccines to US
Novavax expects its COVID-19 vaccine to be authorised in US by May 2021
Inovio completes Phase II enrolment for US trail of COVID-19 vaccine candidate
US FDA Accepts US Merck's Gefapixant New Drug Application for Review
McKesson Begins Distributing the Johnson and Johnson COVID-19 Vaccine